THE IMPACT OF PHARMACOKINETICALLY GUIDED DOSE ESCALATION STRATEGIES IN PHASE-I CLINICAL-TRIALS - CRITICAL-EVALUATION AND RECOMMENDATIONS FOR FUTURE STUDIES

被引：40

作者：

GRAHAM, MA

WORKMAN, P

机构：

[1] CRC Department Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Bearsden, Glasgow

来源：

ANNALS OF ONCOLOGY | 1992年 / 3卷 / 05期

关键词：

PHARMACOKINETIC STRATEGIES; PHASE-I TRIALS; DOSE ESCALATION;

D O I：

10.1093/oxfordjournals.annonc.a058203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Phase I studies requiring multiple dose escalation steps have led to the development of pharmacokinetically guided dose escalation (PGDE) strategies to expedite the conduct of early clinical trials. This article critically reviews PGDE strategies for a number of new anticancer agents including amphethinile, brequinar sodium, iodo-doxorubicin, the anthrapyrazoles (DuP 941, DuP 942 and DuP 937), rhizoxin, and aphidicolin glycinate. The benefits and problems associated with PGDE are examined. Recommendations are made for the optimal deployment of pharmacological information in future phase I studies.

引用

页码：339 / 347

页数：9

共 40 条

[11] FOSTER BJ, IN PRESS EUR J CANC
[12] PRECLINICAL PHARMACOLOGY OF THE ANTHRAPYRAZOLE ANALOG OXANTRAZOLE (NSC-349174, PIROXANTRONE)
FRANK, SK
MATHIESEN, DA
SZURSZEWSKI, M
KUFFEL, MJ
AMES, MM
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (04) : 213 - 218
[13] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE EXPERIMENTAL ANTICANCER AGENT OXANTRAZOLE
FRANK, SK
MATHIESEN, DA
WHITFIELD, LR
AMES, MM
[J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 419 : 225 - 232
[14] FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
[15] INVITRO DNA STRAND SCISSION AND INHIBITION OF NUCLEIC-ACID SYNTHESIS IN L1210 LEUKEMIA-CELLS BY A NEW CLASS OF DNA COMPLEXERS, THE ANTHRA[1,9-CD]PYRAZOL-6(2H)-ONES (ANTHRAPYRAZOLES)
FRY, DW
BORITZKI, TJ
BESSERER, JA
JACKSON, RC
[J]. BIOCHEMICAL PHARMACOLOGY, 1985, 34 (19) : 3499 - 3508
[16] PHARMACOLOGY AND CLINICAL TOXICITY OF 4'-IODO-4'-DEOXYDOXORUBICIN - AN EXAMPLE OF SUCCESSFUL APPLICATION OF PHARMACOKINETICS TO DOSE ESCALATION IN PHASE-I TRIALS
GIANNI, L
VIGANO, L
SURBONE, A
BALLINARI, D
CASALI, P
TARELLA, C
COLLINS, JM
BONADONNA, G
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (06) : 469 - 477
[17] GOLDSMITH MA, 1975, CANCER RES, V35, P1354
[18] GRAHAM MA, 1992, CANCER RES, V52, P603
[19] THE EFFECT OF THE ANTHRAPYRAZOLE ANTITUMOR AGENT-CI941 ON RAT-LIVER MICROSOME AND CYTOCHROME-P-450 REDUCTASE MEDIATED FREE-RADICAL PROCESSES - INHIBITION OF DOXORUBICIN ACTIVATION INVITRO
GRAHAM, MA
NEWELL, DR
BUTLER, J
HOEY, B
PATTERSON, LH
[J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (20) : 3345 - 3351
[20] PRECLINICAL AND PHASE-I STUDIES WITH RHIZOXIN TO APPLY A PHARMACOKINETICALLY GUIDED DOSE-ESCALATION SCHEME
GRAHAM, MA
BISSETT, D
SETANOIANS, A
HAMILTON, T
KERR, DJ
HENRAR, R
KAYE, SB
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (07): : 494 - 500

← 1 2 3 4 →